ChromaDex Corp. and Nestlé Health Science enter global commercial license and supply agreement for TRU NIAGEN®

20 December 2018

LOS ANGELES, California, December 20, 2018 - ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a license and supply agreement with Nestlé Health Science (NHSc). The agreement provides NHSc the exclusive right to include CDXC’s patented nicotinamide riboside ingredient TRU NIAGEN® in NHSc branded medical nutrition, and co-exclusive rights to include TRU NIAGEN® in certain products within the consumer health category. The territories in the agreement include North America, Europe, Latin America, Australia, Japan, and New Zealand.

Please visit the ChromaDex website to view the full press release.